| 11.03 -1.06 (-8.77%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.05 | 1-year : | 19.79 |
| Resists | First : | 14.6 | Second : | 16.95 |
| Pivot price | 14.17 |
|||
| Supports | First : | 10.8 | Second : | 8.98 |
| MAs | MA(5) : | 11.99 |
MA(20) : | 14.59 |
| MA(100) : | 12.83 |
MA(250) : | 9.04  |
|
| MACD | MACD : | -0.8 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.9 |
D(3) : | 8.3 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 17.25 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ANL ] has closed above bottom band by 5.2%. Bollinger Bands are 152.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.89 - 11.96 | 11.96 - 12.01 |
| Low: | 10.74 - 10.83 | 10.83 - 10.9 |
| Close: | 10.9 - 11.03 | 11.03 - 11.14 |
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Fri, 16 Oct 2026
Adlai Nortye Group Ltd. (ANL) stock price, news, quote and history - Yahoo Finance Australia
Fri, 16 Oct 2026
Adlai Nortye Group Ltd. (ANL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 15 Oct 2026
Lilly and Merck will supply a cancer drug at no cost for a trial combining it with Adlai Nortye’s experimental treatment. - Stock Titan
Wed, 14 Oct 2026
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Thu, 08 Oct 2026
Adlai Nortye Group: Only For The Risk Tolerant After Massive Rally (NASDAQ:ANL) - Seeking Alpha
Wed, 30 Sep 2026
With 40.4M shares represented, Adlai Nortye (ANL) shareholders voted on the meeting’s resolutions. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 41.3 (%) |
| Shares Short | 4,400 (K) |
| Shares Short P.Month | 4,120 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.33 |
| Profit Margin | -124.8 % |
| Operating Margin | -44.2 % |
| Return on Assets (ttm) | -8.7 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -16.47 |
| PEG Ratio | 0 |
| Price to Book value | 3.3 |
| Price to Sales | 35.86 |
| Price to Cash Flow | -19.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|